| Metastatic non-small cell lung cancer
Tabrecta vs Tepmetko
Side-by-side clinical, coverage, and cost comparison for metastatic non-small cell lung cancer.Deep comparison between: Tabrecta vs Tepmetko with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTepmetko has a higher rate of injection site reactions vs Tabrecta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tepmetko but not Tabrecta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tabrecta
Tepmetko
At A Glance
Oral
Twice daily
MET kinase inhibitor
Oral
Daily
MET kinase inhibitor
Indications
- Metastatic non-small cell lung cancer
- Metastatic non-small cell lung cancer
Dosing
Metastatic non-small cell lung cancer 400 mg orally twice daily with or without food; swallow tablets whole.
Metastatic non-small cell lung cancer 450 mg orally once daily with food until disease progression or unacceptable toxicity; dose reduction to 225 mg once daily for adverse reactions, with permanent discontinuation if 225 mg is not tolerated.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Edema, nausea, musculoskeletal pain, fatigue, vomiting, dyspnea, cough, decreased appetite
Serious Dyspnea, pneumonia, pleural effusion, musculoskeletal pain, general physical health deterioration, ILD/pneumonitis, edema, vomiting
Most common (>=20%) Edema, nausea, fatigue, musculoskeletal pain, diarrhea, dyspnea, decreased appetite, rash
Serious Pleural effusion, pneumonia, edema, general health deterioration, dyspnea, musculoskeletal pain, pulmonary embolism
Pharmacology
Capmatinib is a kinase inhibitor that targets MET, including the mutant variant produced by exon 14 skipping, inhibiting MET phosphorylation triggered by hepatocyte growth factor binding or MET amplification, and suppressing downstream signaling, proliferation, and survival of MET-dependent cancer cells.
Tepotinib is a kinase inhibitor that targets MET, including variants with exon 14 skipping alterations, inhibiting HGF-dependent and -independent MET phosphorylation and MET-dependent downstream signaling pathways.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tabrecta
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Tepmetko
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Tabrecta
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Tepmetko
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Tabrecta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tepmetko
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Novartis Oncology Universal Co-pay Program: TabrectaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TabrectaView full Tabrecta profile
TepmetkoView full Tepmetko profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.